PepGen's shares plummet 65% as mixed Phase 2 data sparks concern.
ByAinvest
Tuesday, Mar 31, 2026 12:22 pm ET1min read
PEPG--
PepGen's shares have plummeted 65% after releasing mixed Phase 2 data. Despite the disappointing results, a higher dose may offer some relief. The company's shares dropped sharply yesterday and continue to fall today, making it one of the biggest losers in the market. The mixed data has raised concerns about the efficacy of PepGen's treatment.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet